The Experts below are selected from a list of 171 Experts worldwide ranked by ideXlab platform
João Nelson Rodrigues Branco - One of the best experts on this subject based on the ideXlab platform.
-
long term and sustained therapeutic results of a specific Promonocyte cell formulation in refractory angina react refractory angina cell therapy clinical update and cost effective analysis
Cell Transplantation, 2015Co-Authors: Americo Hossne Nelson, Enio Buffolo, Anna Carolina Teixeira De Siqueira Mac Dowell Coimbra, Janaína José Dos Santos Machado, Regina Coeli Dos Santos Goldenberg, Germana Regazzi, Silvia Azevedo, Adriana Luckow Invitti, Eduardo L Cruz, João Nelson Rodrigues BrancoAbstract:Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT® phase I/II clinical trial, our results suggest that a certain cell population, Promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of Promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigra...
-
Long-Term and Sustained Therapeutic Results of a Specific Promonocyte Cell Formulation in Refractory Angina: ReACT(®) (Refractory Angina Cell Therapy) Clinical Update and Cost-Effective Analysis.
Cell transplantation, 2014Co-Authors: Americo Hossne Nelson, L. Eduardo Cruz, Enio Buffolo, Anna Carolina Teixeira De Siqueira Mac Dowell Coimbra, Janaína José Dos Santos Machado, Regina Coeli Dos Santos Goldenberg, Germana Regazzi, Silvia Azevedo, Adriana Luckow Invitti, João Nelson Rodrigues BrancoAbstract:Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT® phase I/II clinical trial, our results suggest that a certain cell population, Promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of Promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigra...
Americo Hossne Nelson - One of the best experts on this subject based on the ideXlab platform.
-
long term and sustained therapeutic results of a specific Promonocyte cell formulation in refractory angina react refractory angina cell therapy clinical update and cost effective analysis
Cell Transplantation, 2015Co-Authors: Americo Hossne Nelson, Enio Buffolo, Anna Carolina Teixeira De Siqueira Mac Dowell Coimbra, Janaína José Dos Santos Machado, Regina Coeli Dos Santos Goldenberg, Germana Regazzi, Silvia Azevedo, Adriana Luckow Invitti, Eduardo L Cruz, João Nelson Rodrigues BrancoAbstract:Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT® phase I/II clinical trial, our results suggest that a certain cell population, Promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of Promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigra...
-
Long-Term and Sustained Therapeutic Results of a Specific Promonocyte Cell Formulation in Refractory Angina: ReACT(®) (Refractory Angina Cell Therapy) Clinical Update and Cost-Effective Analysis.
Cell transplantation, 2014Co-Authors: Americo Hossne Nelson, L. Eduardo Cruz, Enio Buffolo, Anna Carolina Teixeira De Siqueira Mac Dowell Coimbra, Janaína José Dos Santos Machado, Regina Coeli Dos Santos Goldenberg, Germana Regazzi, Silvia Azevedo, Adriana Luckow Invitti, João Nelson Rodrigues BrancoAbstract:Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT® phase I/II clinical trial, our results suggest that a certain cell population, Promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of Promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigra...
Adriana Luckow Invitti - One of the best experts on this subject based on the ideXlab platform.
-
long term and sustained therapeutic results of a specific Promonocyte cell formulation in refractory angina react refractory angina cell therapy clinical update and cost effective analysis
Cell Transplantation, 2015Co-Authors: Americo Hossne Nelson, Enio Buffolo, Anna Carolina Teixeira De Siqueira Mac Dowell Coimbra, Janaína José Dos Santos Machado, Regina Coeli Dos Santos Goldenberg, Germana Regazzi, Silvia Azevedo, Adriana Luckow Invitti, Eduardo L Cruz, João Nelson Rodrigues BrancoAbstract:Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT® phase I/II clinical trial, our results suggest that a certain cell population, Promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of Promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigra...
-
Long-Term and Sustained Therapeutic Results of a Specific Promonocyte Cell Formulation in Refractory Angina: ReACT(®) (Refractory Angina Cell Therapy) Clinical Update and Cost-Effective Analysis.
Cell transplantation, 2014Co-Authors: Americo Hossne Nelson, L. Eduardo Cruz, Enio Buffolo, Anna Carolina Teixeira De Siqueira Mac Dowell Coimbra, Janaína José Dos Santos Machado, Regina Coeli Dos Santos Goldenberg, Germana Regazzi, Silvia Azevedo, Adriana Luckow Invitti, João Nelson Rodrigues BrancoAbstract:Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT® phase I/II clinical trial, our results suggest that a certain cell population, Promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of Promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigra...
Silvia Azevedo - One of the best experts on this subject based on the ideXlab platform.
-
long term and sustained therapeutic results of a specific Promonocyte cell formulation in refractory angina react refractory angina cell therapy clinical update and cost effective analysis
Cell Transplantation, 2015Co-Authors: Americo Hossne Nelson, Enio Buffolo, Anna Carolina Teixeira De Siqueira Mac Dowell Coimbra, Janaína José Dos Santos Machado, Regina Coeli Dos Santos Goldenberg, Germana Regazzi, Silvia Azevedo, Adriana Luckow Invitti, Eduardo L Cruz, João Nelson Rodrigues BrancoAbstract:Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT® phase I/II clinical trial, our results suggest that a certain cell population, Promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of Promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigra...
-
Long-Term and Sustained Therapeutic Results of a Specific Promonocyte Cell Formulation in Refractory Angina: ReACT(®) (Refractory Angina Cell Therapy) Clinical Update and Cost-Effective Analysis.
Cell transplantation, 2014Co-Authors: Americo Hossne Nelson, L. Eduardo Cruz, Enio Buffolo, Anna Carolina Teixeira De Siqueira Mac Dowell Coimbra, Janaína José Dos Santos Machado, Regina Coeli Dos Santos Goldenberg, Germana Regazzi, Silvia Azevedo, Adriana Luckow Invitti, João Nelson Rodrigues BrancoAbstract:Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT® phase I/II clinical trial, our results suggest that a certain cell population, Promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of Promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigra...
Germana Regazzi - One of the best experts on this subject based on the ideXlab platform.
-
long term and sustained therapeutic results of a specific Promonocyte cell formulation in refractory angina react refractory angina cell therapy clinical update and cost effective analysis
Cell Transplantation, 2015Co-Authors: Americo Hossne Nelson, Enio Buffolo, Anna Carolina Teixeira De Siqueira Mac Dowell Coimbra, Janaína José Dos Santos Machado, Regina Coeli Dos Santos Goldenberg, Germana Regazzi, Silvia Azevedo, Adriana Luckow Invitti, Eduardo L Cruz, João Nelson Rodrigues BrancoAbstract:Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT® phase I/II clinical trial, our results suggest that a certain cell population, Promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of Promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigra...
-
Long-Term and Sustained Therapeutic Results of a Specific Promonocyte Cell Formulation in Refractory Angina: ReACT(®) (Refractory Angina Cell Therapy) Clinical Update and Cost-Effective Analysis.
Cell transplantation, 2014Co-Authors: Americo Hossne Nelson, L. Eduardo Cruz, Enio Buffolo, Anna Carolina Teixeira De Siqueira Mac Dowell Coimbra, Janaína José Dos Santos Machado, Regina Coeli Dos Santos Goldenberg, Germana Regazzi, Silvia Azevedo, Adriana Luckow Invitti, João Nelson Rodrigues BrancoAbstract:Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT® phase I/II clinical trial, our results suggest that a certain cell population, Promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of Promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigra...
